MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS

Patients with MYC-driven Group 3 medulloblastoma (MB) show particularly poor outcome. It was previously shown that MYC-driven MBs are highly sensitive to class I histone deacetylase inhibition (HDACi). We studied the molecular effects of the class I HDACi entinostat in MYC-driven MB cells to identif...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Vollmer, Johanna, Ecker, Jonas, Hielscher, Thomas, Valinciute, Gintvile, Oppermann, Sina, Peterziel, Heike, Oehme, Ina, Witt, Olaf, Milde, Till
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Medulloblastoma (Research)
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715328/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.535
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados